The Vizsla's health list names cancer three times — hemangiosarcoma, lymphoma and cancer generally — and for a 45 to 65 pound breed that is a significant weight of risk.
Hemangiosarcoma is a cancer of blood vessel lining, usually arising in the spleen or the heart. Its defining feature is silence: it grows without symptoms and then announces itself by bleeding. The typical presentation is a middle-aged or older dog that becomes suddenly weak, has pale gums, a distended abdomen, or simply collapses. There is no routine screening test, so the practical advice is behavioural — sudden unexplained weakness or pale gums in an older Vizsla is an emergency.
Lymphoma is a cancer of the lymphatic system and it does give a warning sign that owners can check for: enlarged lymph nodes, most easily felt under the jaw, in front of the shoulders and behind the knees. Firm, painless, symmetrical swellings in those places warrant an appointment. Lymphoma responds to treatment better than most canine cancers, and early detection matters.
The rest of the list runs hip dysplasia, progressive retinal atrophy, hypothyroidism, epilepsy, heart problems, ear infections and sebaceous adenitis. Epilepsy is worth asking a breeder about specifically, as is any cancer history in the line — a breeder who tracks longevity and cause of death across three generations is telling you something valuable.
The Malamute's list is more orthopaedic and less oncological: hip and elbow dysplasia, bloat, hypothyroidism, epilepsy, progressive retinal atrophy, hereditary cataracts, zinc-responsive dermatosis and inherited polyneuropathy.
The lifespans are identical at 10 to 14 years, which is a poor result for a medium breed and a good one for a large one — and the cancer list is most of the reason why.